Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis

BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9) is an important regulator of low-density lipoprotein receptor (LDLR) and plasma levels of LDL cholesterol (LDL-C). PCSK9 inhibition is an efficient therapeutic approach for the treatment of dyslipidemia. We tested the therapeutic effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Momtazi-Borojeni, Amir Abbas, Jaafari, Mahmoud Reza, Badiee, Ali, Banach, Maciej, Sahebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902459/
https://www.ncbi.nlm.nih.gov/pubmed/31818299
http://dx.doi.org/10.1186/s12916-019-1457-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902459/
https://www.ncbi.nlm.nih.gov/pubmed/31818299
http://dx.doi.org/10.1186/s12916-019-1457-8

Ejemplares similares